Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 10/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | CSNK1D | P48730 | 9/20 | 0.42 |
| ▸ | CSNK1E | P49674 | 9/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
| ▸ | FLT1 | P17948 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5954829 | 0.89 | CSNK1D (0.44) | KDRJAK1CSNK1DCSNK1E | |
| SCHEMBL5955486 | 0.86 | KDR (0.43) | KDRJAK1CSNK1DCSNK1EAURKA | |
| SCHEMBL253143 | 0.86 | KDR (0.46) | KDRJAK1CSNK1DCSNK1EAURKA | |
| SCHEMBL5954590 | 0.84 | JAK1 (0.48) | KDRJAK1CSNK1DCSNK1EAURKA | |
| SCHEMBL5954839 | 0.83 | CSNK1D (0.46) | KDRCSNK1DCSNK1E | |
| SCHEMBL252421 | 0.83 | KDM4E (0.39) | KDRJAK1 | |
| SCHEMBL5955234 | 0.82 | CSNK1D (0.42) | KDRCSNK1DCSNK1E | |
| SCHEMBL5954413 | 0.82 | CSNK1D (0.42) | KDRJAK1CSNK1DCSNK1E | |
| SCHEMBL2747202 | 0.82 | KDR (0.47) | KDRCSNK1DCSNK1EBRAF | |
| SCHEMBL5954406 | 0.81 | CSNK1D (0.44) | KDRCSNK1DCSNK1E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178534-B2 | cMET inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-15 | — | — | US | claimed |
| US-20130315895-A1 | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-28 | — | — | US | disclosed |
| EP-2588107-A1 | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET | Takeda Pharmaceutical Company Limited (JP) | 2013-05-08 | — | — | EP | disclosed |
| US-8178534-B2 | cMET inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-15 | — | — | US | disclosed |
| US-8178534-B2 | cMET inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-15 | — | — | US | disclosed |
| US-8178534-B2 | cMET inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-15 | — | — | US | disclosed |
| WO-2012003338-A1 | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-01-05 | — | — | WO | disclosed |
| WO-2012003338-A1 | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-01-05 | — | — | WO | disclosed |
| EP-2313407-A1 | cMET INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2011-04-27 | — | — | EP | disclosed |
| US-20100063054-A1 | cMET INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-11 | — | — | US | disclosed |
| US-20100063054-A1 | cMET INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-11 | — | — | US | disclosed |
| US-20100063054-A1 | cMET INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-11 | — | — | US | disclosed |
| WO-2010019899-A1 | cMET INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | WO | disclosed |
| WO-2010019899-A1 | cMET INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130315895-A1 | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET | HGF, MET, HGFAC | KDR 142/4885JAK1 325/4885CSNK1D 2737/4885 |
| US-20100063054-A1 | cMET INHIBITORS | CEPT1, LCAT, GNMT | KDR 1387/4885JAK1 396/4885CSNK1D 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.